A U.S. court has temporarily halted the Pentagon's move to designate Chinese biopharmaceutical contract development and manufacturing organization (CDMO) WuXi AppTec as a "Chinese military corporation."
The main point of the decision is that the Pentagon may have misinterpreted evidence when assessing WuXi AppTec's ties to the Chinese government and military.
According to foreign media and the biotech industry on the 12th, the U.S. District Court for the District of Columbia recently issued a preliminary injunction in a suit WuXi AppTec filed challenging the Ministry of National Defense's "1260H designation."
The order bars the Ministry of National Defense from taking additional actions based on the designation while the main case proceeds, but it does not overturn WuXi AppTec's designation as a Chinese military corporation. As a result, for the time being the Ministry of National Defense cannot "enforce or implement the 1260H designation, or take other actions pursuant to it."
The crux of the court's view is that it did more than simply accept WuXi AppTec's claims; it acknowledged the possibility that there were flaws in the Pentagon's decision-making process itself. The court also found that even if WuXi AppTec later prevails, the harm from the Pentagon's 1260H designation could be difficult to remedy.
In fact, WuXi AppTec is said to have suffered damages after the designation, including work stoppages, project cancellations, and transfers of projects to competing CDMOs. The court is seen as having considered that such harm may be hard to reverse after a verdict in the main case.
After the court's decision, WuXi AppTec said, "Current business operations are fully normal," adding that it would focus on supporting medicines needed by customers and patients.
◇ U.S. Ministry of National Defense: "Tied to Chinese government and military" vs. WuXi AppTec: "A clear mistake"
The Pentagon placed WuXi AppTec on the 1260H list in June. The roster designates corporations that the U.S. Ministry of National Defense determines are linked to China's military and defense industry, including the People's Liberation Army (PLA).
The Ministry of National Defense reportedly took issue with indirect ownership ties between WuXi AppTec and Chinese government bodies. Its cited grounds included ties to the State-owned Assets Supervision and Administration Commission (SASAC) under the China State Council and links to the State Administration of Science, Technology and Industry for National Defense (SASTIND), which handles China's defense industry policy. Ties to the PLA were also among the suspicions raised by the Ministry of National Defense.
WuXi AppTec strongly denied this.
The company argued it is not owned or controlled by, or affiliated with, any Chinese government or military-related body, and does not provide services to the PLA. It also said it is not connected to China's defense industrial base or the "military-civil fusion" program.
At the time, WuXi AppTec pushed back, calling the Pentagon's designation a "clear mistake," and filed suit in late June. In its latest decision, the court was also said to have pointed to the possibility that the Ministry of National Defense misinterpreted evidence when assessing WuXi AppTec's ties to the Chinese government and military.
However, the court has not finally accepted WuXi AppTec's claims. A final judgment on whether the Ministry of National Defense's 1260H designation was lawful will be rendered through the main proceedings.
◇ 1260H designation intersects with the Biosecure Act
WuXi AppTec is responding sensitively to the 1260H designation because U.S. restrictions on Chinese biotech could connect to the Biosecure Act.
Targeting China's biotech industry, the Biosecure Act would restrict the U.S. federal government from procuring or contracting equipment and services provided by certain biotech companies deemed national security risks.
The U.S. government and Congress have tightened restrictions on China's biotech industry since 2024. On and off Capitol Hill, WuXi AppTec and its sister company WuXi Biologics have been cited as target corporations.
WuXi Biologics is a biopharmaceutical CDMO corporation spun off from WuXi AppTec in 2017. Because it counts U.S. drugmakers as major customers, observers have said it could be affected if future U.S. restrictions are expanded across the WuXi group.
With the court's decision, WuXi AppTec has at least escaped additional disadvantages stemming from the 1260H designation for now.
However, the overall U.S. policy of checking China's biotech industry has not changed. As the U.S. tightened restrictions on Chinese CDMOs such as WuXi AppTec and WuXi Biologics, the prevailing view had been that global drugmakers might shift manufacturing and research and development volumes to other suppliers.
From that perspective, Samsung Biologics(207940), Lotte Biologics, and other domestic CDMO corporations were expected to absorb some of that volume, but the U.S. court's brake has reduced the likelihood that WuXi AppTec's U.S. business will shrink immediately. Domestic corporations, Chinese corporations, and global clients that outsource production to CDMOs alike now face greater uncertainty.
Industry analysts said the U.S. stance of reducing supply chain dependence on China's biotech industry itself has not changed, so depending on the outcome of the main case and the specific scope of the Biosecure Act's application, opportunities for domestic CDMOs could grow again.